Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider outpatient cardiac rehabilitation programs for patients with a history of the following conditions and procedures to be eligible for coverage:

- Acute myocardial infarction (heart attack) within the preceding 12 months;
- Coronary artery bypass graft surgery;
- Percutaneous transluminal coronary angioplasty or coronary stenting;
- Heart valve surgery;
- Heart or heart-lung transplantation;
- Current stable angina pectoris; and
- Compensated heart failure.

The following components must be included in cardiac rehabilitation programs:

- Physician-prescribed exercise each day cardiac rehabilitation services are provided;
- Cardiac risk factor modification;
- Psychosocial assessment;
- Outcomes assessment; and
- Individualized treatment plan detailing how each of the above components are utilized.

A cardiac rehabilitation exercise program is eligible for coverage for 3 sessions per week up to a 12-week period (36 sessions). Programs should start within 90 days of the cardiac event (with exception of acute myocardial infarction as noted above) and be completed within 6 months of the cardiac event.

A comprehensive evaluation may be performed before initiation of cardiac rehabilitation to evaluate the patient and determine an appropriate exercise program. In addition to a medical examination, an electrocardiogram stress test may be performed. An additional stress test may be performed at the completion of the program. Physical and/or occupational therapy are not medically necessary in conjunction with cardiac rehabilitation unless performed for an unrelated diagnosis.
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers cardiac rehabilitation in the outpatient setting when criteria are not to be investigational.*

Based on review of available data, the Company considers repeat participation in an outpatient cardiac rehabilitation program in the absence of another qualifying cardiac event to be investigational.*

Based on review of available data, the Company considers Intensive cardiac rehabilitation with the Ornish Program for Reversing Heart Disease or Pritikin Program to be investigational.*

Background/Overview
HEART DISEASE
Heart disease is the leading cause of mortality in the United States, accounting for more than half of all deaths. Coronary artery disease (CAD) is the most common cause of heart disease. In a 2015 update on heart disease and stroke statistics from the American Heart Association, it was estimated that 635,000 Americans have a new coronary attack (first hospitalized myocardial infarction or coronary heart disease death) and 300,000 have a recurrent attack annually. Both CAD and various other disorders—structural heart disease and other genetic, metabolic, endocrine, toxic, inflammatory, and infectious causes—can lead to the clinical syndrome of heart failure, of which there are about 650,000 new cases in the U.S. annually. Given the burden of heart disease, preventing secondary cardiac events and treating the symptoms of heart disease and heart failure have received much attention from national organizations.

In 1995, the U.S. Public Health Service (USPHS) defined cardiac rehabilitation services as, in part, “comprehensive, long-term programs involving medical evaluation, prescribed exercise, cardiac risk factor modification, education, and counseling…. [These programs are] designed to limit the physiologic and psychological effects of cardiac illness, reduce the risk for sudden death or reinfarction, control cardiac symptoms, stabilize or reverse the atherosclerotic process, and enhance the psychosocial and vocational status of selected patients.” This USPHS guideline recommended cardiac rehabilitation services for patients with coronary heart disease and with heart failure, including those awaiting or following cardiac transplantation. A 2010 definition of cardiac rehabilitation from the European Association of Cardiovascular Prevention and Rehabilitation stated: “Cardiac rehabilitation can be viewed as the clinical application of preventive care by means of a professional multi-disciplinary integrated approach for comprehensive risk reduction and global long-term care of cardiac patients.” Since release of the USPHS guideline, other societies, including the American Heart Association (2005) and the Heart Failure Society of America (2010) have developed guidelines on the role of cardiac rehabilitation in patient care.

FDA or Other Governmental Regulatory Approval
U.S. Food and Drug Administration (FDA)
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

Not applicable.

Centers for Medicare and Medicaid Services (CMS)

Cardiac Rehabilitation
Medicare has had a national coverage determination (NCD) for cardiac rehabilitation since 1989. There was a change in Medicare coverage for cardiac rehabilitation in January 2010. Indications for coverage remained the same; namely, patients who have experienced at least one of the following:

- Acute myocardial infarction within the preceding 12 months
- Coronary artery bypass surgery
- Current stable angina pectoris
- Heart valve repair or replacement
- Percutaneous transluminal coronary angioplasty (PTCA) or coronary stenting
- Heart or heart-lung transplant

As of February 2014, a change was made to the patient criteria to expand eligibility for cardiac rehabilitation to patients with the following: “Stable, chronic heart failure, defined as patients with left ventricular ejection fraction of 35% or less and New York Heart Association (NYHA) class II to IV symptoms despite being on optimal heart failure therapy for at least 6 weeks. Stable patients are defined as patients who have not had recent (≤ 6 weeks) or planned (≤ 6 months) major cardiovascular hospitalizations or procedures.”

The 2010 criteria specify the required components of cardiac rehabilitation programs. Programs must include all of the following:

- Physician-prescribed exercise each day cardiac rehabilitation items and services are furnished;
- Cardiac risk factor modification, including education, counseling and behavioral intervention at least once during the program, tailored to patients’ individual needs;
- Psychosocial assessment;
- Outcomes assessment; and
- An individualized treatment plan detailing how components are utilized for each patient.”

In addition, criteria on the frequency and duration of cardiac rehabilitation services were updated. On or before December 31, 2009, Medicare covered 18 weeks of cardiac rehabilitation services, with contractor discretion to cover services beyond 18 weeks. Coverage could not exceed a total of 72 sessions for 36 weeks.

Beginning in January 2010, the criteria were updated:

“Cardiac rehabilitation items and services must be furnished in a physician’s office or a hospital outpatient setting. All settings must have a physician immediately available and accessible for medical consultations and emergencies at all time items and services are being furnished under the program....

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

Cardiac rehabilitation program sessions are limited to a maximum of 2 1-hour sessions per day for up to 36 sessions over up to 36 weeks, with the option of an additional 36 sessions over an extended period of time if approved by the Medicare contractor.

**Intensive Cardiac Rehabilitation**

Beginning in January 2010, Medicare added intensive cardiac rehabilitation as a benefit. Intensive cardiac rehabilitation programs must be approved by Medicare on an individual basis.

The NCD described intensive cardiac rehabilitation in the following manner:

"Intensive cardiac rehabilitation (ICR) refers to a physician-supervised program that furnishes cardiac rehabilitation services more frequently and often in a more rigorous manner. As required by §1861(eee)(4)(A) of the Social Security Act (the Act), an ICR program must show, in peer-reviewed published research, that it accomplished one or more of the following for its patients: (1) positively affected the progression of coronary heart disease; (2) reduced the need for coronary bypass surgery; and, (3) reduced the need for percutaneous coronary interventions. The ICR program must also demonstrate through peer-reviewed published research that it accomplished a statistically significant reduction in five or more of the following measures for patients from their levels before cardiac rehabilitation services to after cardiac rehabilitation services: (1) low density lipoprotein; (2) triglycerides; (3) body mass index; (4) systolic blood pressure; (5) diastolic blood pressure; and, (6) the need for cholesterol, blood pressure, and diabetes medications. Individual ICR programs must be approved through the national coverage determination process to ensure that they demonstrate these accomplishments."

In 2010, CMS also issued 2 decision memos on specific programs. One stated that the Ornish Program for Reversing Heart Disease met the ICR program requirements and was included on the list of approved ICR programs. It provided the following description of the Ornish Program: “The Ornish Program for Reversing Heart Disease (also known as the Multisite Cardiac Lifestyle Intervention Program, Multicenter Cardiac Lifestyle Intervention Program and the Lifestyle Heart Trial program) ...incorporates comprehensive lifestyle modifications including exercise, a low-fat diet, smoking cessation, stress management training, and group support sessions. Over the years, the Ornish program has been refined but continues to focus on these specific risk factors.”

The other stated that the Pritikin Program met program requirements and was included on the list of approved ICR programs. As described in the decision memo: “The Pritikin program (also known as the Pritikin Longevity Program) evolved into a comprehensive program that is provided in a physician’s office and incorporates a specific diet (10%–15% of calories from fat, 15%–20% from protein, 65%–75% from complex carbohydrates), exercise and counseling lasting 21-26 days. An optional residential component is also available for participants.”
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

Rationale/Source
OUTPATIENT CARDIAC REHABILITATION FOR HEART DISEASE
Many randomized controlled trials (RCTs) have been published comparing cardiac rehabilitation with usual care for patients with established heart disease, and a number of meta-analyses of RCTs have been performed, which are the focus of this review. Systematic reviews that include observational studies are also discussed.

Systematic Reviews
Systematic Reviews of RCTs
In 2012, Oldridge identified 6 independent meta-analyses published since 2000 that reported outcomes from 71 RCTs (total N=13,824 patients) following cardiac rehabilitation interventions. The RCTs included in the meta-analyses enrolled patients with myocardial infarction (MI), coronary heart disease (CHD), angina, percutaneous coronary intervention (PCI), and/or coronary artery bypass graft (CABG). RCTs compared cardiac rehabilitation programs (exercise only and/or comprehensive rehabilitation) with usual care. Cardiac rehabilitation was associated with a statistically significant (p<0.05) reduction in all-cause mortality in 4 of the 5 meta-analyses that reported this outcome. In pooled analysis, cardiac rehabilitation was associated with a 18.5% mean reduction in all-cause mortality. In addition, cardiac rehabilitation was associated with a statistically significant reduction in cardiac mortality in 3 of the 4 meta-analyses that reported disease-specific mortality as an outcome.

Two of the meta-analyses on cardiac rehabilitation were conducted by Cochrane. One included patients with CHD and the other focused on patients with systolic heart failure. Both addressed exercise-based cardiac rehabilitation programs (exercise alone or as part of a comprehensive program). In 2016, Anderson et al updated a 2011 Cochrane review addressing exercise-based cardiac rehabilitation for individuals with CHD. Reviewers included RCTs of exercise-based interventions with at least 6 months of follow-up compared with no-exercise controls in patients with MI, CABG, or PCI, or with angina pectoris or coronary artery disease. The updated review included 63 RCTs (total N=14,486 individuals), of which 16 trials were new since the 2011 update. Reviewers reported that the overall risk of bias was unclear, although the quality of reporting improved with more recent trials. Due to the nature of the intervention, patients were not blinded to treatment group in any of the studies, but 16 (25%) of 62 studies reported details of blinded assessment of study outcomes. In pooled analysis, cardiac rehabilitation was not significantly associated with overall mortality. However, among 27 studies, cardiac rehabilitation was significantly associated with reduced cardiovascular mortality (292/3850 for cardiac rehabilitation subjects vs 375/3619 for control subjects; relative risk [RR], 0.74; 95% confidence interval [CI], 0.64 to 0.86). Rates of MI, CABG, and PCI were not significantly associated with receiving cardiac rehabilitation.

A 2014 Cochrane review by Taylor et al reported on studies assessing cardiac rehabilitation in patients with heart failure. Reviewers included 33 trials (total N=4740 individuals), with 14 studies added with the latest update. One large trial (HF-ACTION) contributed 50% of patients; most other studies were small and single center. The population was predominantly patients with heart failure with reduced ejection fraction and New York Heart Association class II and III heart failure. The trials had a moderate risk of bias; many earlier studies (particularly pre-2000) had insufficient detail to permit assessment of risk of bias. In the 25 studies
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

that reported all-cause mortality up to 12-month follow-up, there was no difference in pooled mortality between groups (RR=0.93; 95% CI, 0.69 to 1.27; p=0.59). For health-related quality of life (QOL), most studies reported disease-specific QOL with the Minnesota Living With Heart Failure (MLWHF) questionnaire. Although there was statistical heterogeneity in the differences in MLWHF scores between exercise and control groups, there was a significant improvement in MLWHF scores with exercise in pooled analysis (mean difference, -5.8; 95% CI, -9.2 to -2.4, p=0.001). Most studies selected for the Cochrane review, including the HF-ACTION trial, were exercise-only interventions; thus, conclusions cannot be drawn from this review about the impact of comprehensive cardiac rehabilitation programs on mortality or hospital admissions in patients with heart failure. Reviewers did not require that studies only include patients with compensated heart failure.

Systematic Reviews of Observational Studies
In 2017, Sumner et al published a systematic review of controlled observational studies evaluating cardiac rehabilitation in patients diagnosed with acute MI. Cardiac rehabilitation interventions consisted of structured multicomponent programs that included exercise in addition to at least one of the following: education, information, health behavior change, and psychological or social support. Usual care interventions, generally supervised medical interventions, were the control conditions. Ten studies met reviewers’ eligibility criteria. In a meta-analysis of 5 studies reporting all-cause mortality (unadjusted outcome), there was a significantly lower risk of death in the group that received cardiac rehabilitation (odds ratio [OR], 0.25; 95% CI, 0.16 to 0.40). Three studies that reported an adjusted analysis of all-cause mortality also found a significant benefit from cardiac rehabilitation (OR=0.47; 95% CI, 0.38 to 0.59). Similarly, a meta-analysis of 3 studies reporting cardiac-related mortality (unadjusted analysis) found a significant benefit from cardiac rehabilitation (OR=0.21; 95% CI, 0.12 to 0.37). Only 1 study reported an adjusted analysis of cardiac-related mortality so data could not be pooled.

Randomized Controlled Trials
Overall, the evidence from well-conducted systematic reviews suggests that cardiac rehabilitation is associated with reduced cardiovascular mortality in patients with CHD.

Findings of a large, multicenter RCT from the U.K., which evaluated the effectiveness of cardiac rehabilitation in a "real-life" setting, were published by West et al in 2012. Called the Rehabilitation After Myocardial Infarction Trial (RAMIT), the study included patients from 14 centers with established cardiac rehabilitation programs that were multifactorial (including exercise, education, and counseling), involved more than 1 discipline, and provided an intervention lasting a minimum of 10 hours. A total of 1813 patients were randomized—903 to cardiac rehabilitation and 910 to a control condition. Vital status was obtained at 2 years for 99.9% (all but 1 patient) and at 7 to 9 years for 99.4% of patients. By 2 years, 166 patients had died, 82 in the cardiac rehabilitation group and 84 in the control group. The between-group difference in mortality at 2 years (the primary study outcome) was not statistically significant (RR=0.98; 95% CI, 0.74 to 1.30). After 7 to 9 years, 488 patients had died, 245 in the cardiac rehabilitation group and 243 in the control group (RR=0.99; 95% CI, 0.85 to 1.15). In addition, at 1 year, cardiovascular morbidity did not differ significantly between groups. For a combined end point including death, nonfatal MI, stroke, or revascularization, the relative risk was 0.96 (95% CI, 0.88 to 1.07). In discussing the study’s negative
findings, the trial authors noted that medical management of heart disease has improved over time, and patients in the control group may have had better outcomes than in earlier RCTs on this topic. Moreover, an editorial accompanying the publication of the study’s findings emphasized that RAMIT was not an efficacy trial, but rather, a trial evaluating the effectiveness of actual cardiac rehabilitation programs in the U.K. Finally, these results may in part reflect the degree to which clinically based cardiac rehabilitation programs in the U.K. differ from the treatment protocols used in RCTs based in research settings.

A concern raised by the negative findings in the RAMIT trial is that most of the RCTs evaluating cardiac rehabilitation were conducted in an earlier era of heart disease management and may not be relevant to current care. However, RAMIT’s results, along with 15 additional RCTs reported since a 2011 Cochrane review, were included in the updated 2016 Cochrane review, which found improvements in cardiovascular mortality associated with exercise-based cardiac rehabilitation.

Section Summary: Outpatient Cardiac Rehabilitation for Heart Disease
A number of RCTs, systematic reviews of RCTs, and/or observational studies have evaluated outpatient cardiac rehabilitation in patients with heart disease. An overview of 6 meta-analyses found a statistically significant association between cardiac rehabilitation and all-cause mortality and/or cardiac mortality. The available evidence has limitations, including lack of blinded outcome assessment, but, for the survival-related outcomes of interest, this limitation is less critical.

REPEAT OUTPATIENT CARDIAC REHABILITATION
No studies were identified that evaluated the effectiveness of repeat participation in a cardiac rehabilitation program.

INTENSIVE CARDIAC REHABILITATION FOR HEART DISEASE
There is no standard definition for an intensive cardiac rehabilitation program and, thus, specific programs will be reviewed individually. Two programs have been evaluated by CMS and we describe the published evidence supporting these programs next. The ideal study would be an RCT comparing the impact of intensive cardiac rehabilitation and standard cardiac rehabilitation on health outcomes.

Ornish Program for Reversing Heart Disease
Ornish et al conducted an RCT, called the Lifestyle Heart Trial, comparing a version of the Ornish Program for Reversing Heart Disease with usual care. Initial results were reported in 1990 and 5-year results in 1998. Eligibility for the trial included diagnosed coronary artery disease, left ventricular ejection fraction greater than 25%, no MI during the previous 6 weeks, no scheduled for CABG, and not taking lipid-lowering medication. Ninety-four eligible patients were randomized to an intervention group (n=53) or to a usual care control group (n=43). Final consenting was done after randomization; 28 (53%) of patients assigned to the intervention group and 20 (43%) assigned to the control group agreed to participate in the trial.

The Lifestyle intervention consisted of recommending a low-fat vegetarian diet and an individualized exercise regimen. In addition, patients were taught stress management techniques and were taught to practice them at home for at least an hour a day. In addition, twice-weekly group discussions were offered...
to provide social support. It is not clear how long patients attended these group discussion (ie, the number of weeks or months). As reported by Ornish et al (1990), the mean percentage diameter stenosis decreased from 40% at baseline to 37.8% at 1 year in the intervention group and increased from 42.7% to 46.1% in the control group (p=0.001). The frequency and duration of chest pain did not differ between groups. However, during chest pain episodes, at 1 year, the intervention group reported mean chest pain severity of 1.7 (on a 7-point scale) whereas the mean score in the control group was 2.5 (p<0.001).

Twenty (71%) of 28 patients in the intervention group and 15 (75%) of 20 in the control group complete 5-year follow-up. The intervention and control groups did not differ significantly in the number of MI events (2 vs 4), CABGs (2 vs 5), or deaths (2 vs 1). However, the intervention group compared with the control group, had significantly fewer percutaneous transluminal coronary angioplasties (8 vs 14, p<0.050) and cardiac hospitalizations (23 vs 44, p<0.001).

Section Summary: Ornish Program for Reversing Heart Disease
One RCT was identified that evaluated the Ornish Program in patients diagnosed with heart disease, and compared it to usual care. This RCT, which included patients with coronary artery disease but no recent cardiac event, had mixed findings at 1 and 5 years. The trial had a small sample size for a cardiac trial (N=48), and only 35 patients were available for the 5-year follow-up. The Ornish Program is considered by CMS to be an intensive cardiac rehabilitation program, but the program described in this RCT might meet criteria for standard cardiac rehabilitation. No studies were identified that compared the Ornish Program with any other cardiac rehabilitation program.

Pritikin Program
No RCTs evaluating the Pritikin Program were identified. The published evidence on this program consists of case series, and only one of the case series (Barnard et al, 1983) included patients with heart disease. (Other case series included patients without heart failure, eg, those with high cholesterol levels.) Sixty-four patients with documented coronary artery disease attended a 26-day residential treatment program between 1976 and 1977. During the program, patients were encouraged to walk for 30 to 45 minutes twice a day, learned how to prepare foods consistent with the Pritikin diet, and attended over 60 hours of group education classes. Serum samples were taken at baseline and at the end of the program. Patients were called in March 1980 for a follow-up interview and were asked to send in serum samples. At the 3- to 4-year follow-up, 12 (19%) of 64 patients had had bypass surgery and 4 patients had died. Fifty (81%) patients provided serum samples at follow-up and the mean cholesterol level (166 mg/dL, SD=5) was significantly lower than the baseline value (220 mg/dL, SD=6). The trial was limited the lack of a control group, especially a group receiving “standard” outpatient cardiac rehabilitation, and long-term mortality outcomes were not reported.

Section Summary: Pritikin Program
No RCTs have evaluated the Pritikin program; we found 1 case series in patients with heart disease. Conclusions cannot be drawn from these series on the impact of intensive cardiac rehabilitation with the Pritikin program compared with standard outpatient cardiac rehabilitation.
SUMMARY OF EVIDENCE

For individuals who have diagnosed heart disease who receive outpatient cardiac rehabilitation, the evidence includes multiple RCTs and systematic reviews of these trials. Relevant outcomes are overall survival, disease-specific survival, symptoms, and morbid events. Meta-analyses of the available trials have found that cardiac rehabilitation improves health outcomes for select patients, particularly those with coronary heart disease. The available evidence has limitations, including lack of blinded outcome assessment, but, for the survival-related outcomes of interest, this limitation is less critical. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have diagnosed heart disease without a second event who receive repeat outpatient cardiac rehabilitation, the evidence includes no trials. Relevant outcomes are overall survival, disease-specific survival, symptoms, and morbid events. No studies were identified evaluating the effectiveness of repeat participation in a cardiac rehabilitation program. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have diagnosed heart disease who receive intensive cardiac rehabilitation with the Ornish Program for Reversing Heart Disease, the evidence includes 1 RCT and uncontrolled studies. Relevant outcomes are overall survival, disease-specific survival, symptoms, and morbid events. No RCTs have compared the Ornish Program to a “standard” cardiac rehabilitation program; 1 RCT compared it with usual care. The trial included patients with coronary artery disease and no recent cardiac events, and had mixed findings at 1 and 5 years. The trial had a small sample size for a cardiac trial (N=48), and only 35 patients were available for the 5-year follow-up. The Ornish Program is considered by the CMS as an intensive cardiac rehabilitation program, but the program described in the RCT might meet criteria for standard cardiac rehabilitation. No studies were identified comparing the Ornish Program with any other cardiac rehabilitation program. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have diagnosed heart disease who receive intensive cardiac rehabilitation with the Pritikin Program, the evidence includes 1 case series. Relevant outcomes are overall survival, disease-specific survival, symptoms, and morbid events. Studies are needed that compare the impact of intensive cardiac rehabilitation between the Pritikin Program and standard outpatient cardiac rehabilitation programs. The evidence is insufficient to determine the effects of the technology on health outcomes.

References
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017


©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Cardiac Rehabilitation in the Outpatient Setting

Policy # 00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2016 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>4500F, 4510F, 93015, 93016, 93797, 93798</td>
</tr>
<tr>
<td>HCPCS</td>
<td>G0422, G0423, S9472</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>I20.8-I20.9, I21.01-I21.4, I50.1-I50.9, Z94.1, Z94.3, Z95.1-Z95.5, Z98.61</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
Cardiac Rehabilitation in the Outpatient Setting

Policy #  00570
Original Effective Date: 09/20/2017
Current Effective Date: 09/20/2017

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
   A. In accordance with nationally accepted standards of medical practice;
   B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient’s illness, injury or disease; and
   C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient’s illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

†† Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.